Contact Us |

Search 

עברית  

    logoemp

 

slogN

 

dayanews emp nodaya

 

 04 | December | 2014

Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Read more >


 01 | December | 2014

Pluristem Granted Patent in Singapore for its 3D Cell Expansion Technology

Read more >


 25 | November | 2014

Pluristem’s Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences

Read more >


 12 | November | 2014

Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications

Read more >


 10 | November | 2014

Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014

Read more >


27 | October | 2014

Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

Read more >


21 | October | 2014

Pluristem Advances its Second Major Cell Therapy Product Line from Development to Large-Scale Manufacturing

Read more >


 

 

 
 
 
About hp
 

Zami Aberman

Chairman and CEO

 

Zami Aberman

        From the CEO

Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena. We also believe that in cell therapy “the process is the product”, and precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us to continue developing additional candidates for our product portfolio.

 

On October 28 our CFO, Boaz Gur-Lavie, was interviewed by Decision Plus, a media outlet based in Montreal, Canada. The clip can be viewed below. Mr. Gur-Lavie summarized the latest company news, and also reviewed the exciting new regulatory pathways that have emerged in Japan and Europe. Companies such as Pluristem can apply to these pathways, which make it possible to potentially achieve limited commercialization of a product after phase 2 trials if the trial results are compelling and the therapeutic product and targeted indication meets multiple, stringent requirements.

 

        Zami Aberman
        Chairman and CEO

 

 

 

 

 

 

 

Share Button comm

  
Investors hp
 

     Yaky Yanay
     President and COO

 

Yaky Yanay

Pluristem's wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $ 4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014.

 

Read more >> 
 
 

Share Button comm

tech hp
 

Hillit Mannor Shachar, M.D., M.B.A.
VP Business Development

 

Hillit Mannor Shachar

Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market

Pluristem is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded (PLX) cell therapies in Japan.

Read more >>

 
 

Share Button comm

 
 
Investors hp
 

        Boaz Gur-Lavie,         C.P.A., M.B.A.
        CFO 

 

boaz-new

Pluristem released its 10-K and consolidated financial statements for the year ended on June 30th, 2014.

 

Read more >>
 
 

Share Button comm

 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13

 

 

 

catom 02

Share Button
 

The content, text, graphics, data, and services offered herein (the "Content") are provided solely to educate users of this web site on Pluristem and the goods and/or services it provides.  Nothing in the Content should be considered, or used as a substitute for, medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Reliance on the Content or any portion thereof, or other visitors to the web site, is solely at your own risk.